GCIA
BMY.RT

Gabelli & Co Investment Advisers’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-400,701
Closed -$902K – 376
2020
Q3 		$902K Buy
400,701
+18,372
+5% +$52.5K 0.16% 107
2020
Q2 		$1.37M Sell
382,329
-113,406
-23% -$409K 0.31% 68
2020
Q1 		$1.88M Sell
495,735
-19,866
-4% -$65.4K 0.28% 60
2019
Q4 		$1.55M Buy
+515,601
New +$1.34M 0.18% 89

Other funds holding BMY.RT

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BFS
Bard Financial Services Branford, Connecticut $911M AUM 19.14% 1-Year Est. Return
LGP
Leonard Green & Partners Los Angeles, California $2.77B AUM 3.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Gabelli & Co Investment Advisers's BMY.RT Position: Q4 2020 in Review

Gabelli & Co Investment Advisers sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q4 2020, closing a stake of 400,701 shares — an estimated $902K sold.

Gabelli & Co Investment Advisers first reported a position in BMY.RT in Q4 2019 and held it in 4 quarters. The position peaked at $1.88M in Q1 2020. 546 funds tracked by Wall St. Rank hold BMY.RT as of Q4 2020.

  • Gabelli & Co Investment Advisers reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q4 2020 after selling out during the quarter.
  • Gabelli & Co Investment Advisers sold 400,701 Bristol-Myers Squibb Company Contingent Value Rights shares in Q4 2020, an estimated $902K.
  • Gabelli & Co Investment Advisers first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 4 quarters.
  • Gabelli & Co Investment Advisers's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $1.88M in Q1 2020.
  • 546 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q4 2020.

Based on Gabelli & Co Investment Advisers's 13F filing for Q4 2020, filed 5 Feb 2021.